Plasma from individuals with a higher WMH burden was associated with increased BBB disruption in hBMEC. 5 key findings →
Participants: 155 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Research
27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
There are many reports about the comorbidity of NPH and other neurodegenerative diseases1–3; the primary findings in neuropathological studies of patients with NPH include amyloid plaques and hyperphosphorylated tau protein inclusions.2,4 This suggests that proteinopathy may be one of the potential causes of NPH. 5 key findings →
Design: cohort study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The glymphatic system, a vital brain perivascular network for waste clearance, hinges on the functionality of the aquaporin 4 (AQP4) water channel. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This raises the suggestion that a decreased neurovascular coupling in the disease process of AD is related to comorbid small vessel disease. 2 key findings →
Participants: 119 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 1154 participants (46% men, mean age 70.9±8.7 years), 92 (8%) developed stroke over a median follow-up of 8.6 years (Q1-Q3: 5.1-12.5). 5 key findings →
Participants: 1,154 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cerebral small vessel disease (cSVD) is associated with vascular cognitive impairment, dementia, and stroke. 3 key findings →
Design: cross-sectional Participants: 59 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The mean age of the participants was 68 ± 9 years and 39% were female. 5 key findings →
Design: post-hoc analysis Participants: 759 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Small vessel disease encompasses lacunar stroke, white matter hyperintensities, lacunes and microbleeds. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Higher adherence to the MeDi is associated with reduced cerebrovascular disease burden. 3 key findings →
Participants: 46 Evidence: low
Full summary, score breakdown and related studies → Original source
Carotid atherosclerosis markers were associated with MRI indices of brain ischemia and aging and with cognitive impairment in a community-based sample of middle-aged adults. 5 key findings →
Participants: 1,975 Evidence: low
Full summary, score breakdown and related studies → Original source
Temporoparietal hypoperfusion on SPECT is common to both AD and DLB. 2 key findings →
Participants: 23 Evidence: low
Full summary, score breakdown and related studies → Original source
Inflammatory processes may be involved in the pathogenesis of cerebral small-vessel disease, in particular, the development of white matter lesions. 3 key findings →
Participants: 1,033 Evidence: low
Full summary, score breakdown and related studies → Original source
Our results suggest that different subcortical areas have different vulnerabilities to ischemia in CADASIL. 4 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source
Among participants with normal cognition, higher aortic PWV related to lower frontal lobe CBF (β=-0.43; P=0.04) and higher CVR in the whole brain (β=0.11; P=0.02), frontal lobes (β=0.12; P<0.05), temporal lobes (β=0.11; P=0.02), and occipital lobes (β=0.14; P=0.01). 3 key findings →
Participants: 155 Evidence: low
Full summary, score breakdown and related studies → Original source
Aging is associated with chronic systemic inflammation, which contributes to the development of many age-related diseases, including vascular disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
46/100
Our findings imply that the current version of the Boston criteria may not be sufficient enough to remove non-CAA cases from a cognitively impaired population, especially in the absence of cSS. 4 key findings →
Participants: 27 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Advances in human genetics have implicated a growing number of genes in neurodegenerative diseases, providing insight into pathological processes. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Senescence is a leading cause of mortality, disability, and non-communicable chronic diseases in older adults. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ANOVA revealed significant group differences in lateral ventricular SUVR across the Alzheimer, mild cognitive impairment, and healthy control groups ( P = 0.004). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dietary consumption of baked or broiled fish is related to larger gray matter volumes independent of omega-3 fatty acid content. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
46/100
FA reduction in forceps minor was the most significant area of difference between AD and VaD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These results suggest that mechanisms leading to atherosclerosis might also lead to an increased number of perivascular spaces. 5 key findings →
Participants: 706 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Maintenance of brain function depends on a constant blood supply. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This review of age-related brain microvascular pathologies focuses on topics studied by this laboratory, including anatomy of the blood supply, tortuous vessels, venous collagenosis, capillary remnants, vascular density and microembolic brain injury. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We investigated the changes of sulcal shape (average mean curvature in folded regions and sulcal depth) in mild cognitive impairment (MCI) and Alzheimer's disease (AD) using quantitative surface-based methods in a large sample of magnetic resonance imaging data. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From across this tag
10 of the 902 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS)
- Mitochondrial Reactive Oxygen Species Production in Vascular Dementia Following Experimental Diabetes
- Vitamin D and brain health: an observational and Mendelian randomization study
- Microglia exacerbate white matter injury via complement C3/C3aR pathway after hypoperfusion
- Cognitive dispersion is associated with white matter hyperintensities in amyloid positive older adults
- Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review
- Cerebral small-vessel disease and decline in information processing speed, executive function and memory
- Network dysfunction after traumatic brain injury
- Depression and vascular disease: what is the relationship?
- Role of microbiota-derived short-chain fatty acids in nervous system disorders
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →